Inozyme Net Cash Flow or Change in Cash and Cash Equivalents vs Net Cash Flow Investment Acquisitions and Disposals Analysis

INZY Stock  USD 7.66  0.27  3.65%   
Trend analysis of Inozyme PharmaInc balance sheet accounts such as Total Current Liabilities of 10.4 M or Total Stockholder Equity of 87.9 M provides information on Inozyme PharmaInc's total assets, liabilities, and equity, which is the actual value of Inozyme PharmaInc to its prevalent stockholders. By breaking down trends over time using Inozyme PharmaInc balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inozyme PharmaInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
For more information on how to buy Inozyme Stock please use our How to Invest in Inozyme PharmaInc guide.

About Inozyme Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Inozyme PharmaInc at a specified time, usually calculated after every quarter, six months, or one year. Inozyme PharmaInc Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Inozyme PharmaInc and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Inozyme currently owns. An asset can also be divided into two categories, current and non-current.

Inozyme PharmaInc Balance Sheet Chart

Inozyme PharmaInc Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Inozyme PharmaInc uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, Inozyme PharmaInc's Accumulated Other Comprehensive Income is fairly stable compared to the past year. Capital Stock is likely to rise to 6,300 in 2024, whereas Total Assets are likely to drop slightly above 132.8 M in 2024.

Total Assets

Total assets refers to the total amount of Inozyme PharmaInc assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Inozyme PharmaInc books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Inozyme PharmaInc balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Inozyme PharmaInc are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.
Most indicators from Inozyme PharmaInc's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Inozyme PharmaInc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inozyme PharmaInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
For more information on how to buy Inozyme Stock please use our How to Invest in Inozyme PharmaInc guide.Selling General Administrative is likely to drop to about 14.5 M in 2024. Issuance Of Capital Stock is likely to drop to about 63.3 M in 2024
 2021 2022 2023 2024 (projected)
Interest Income211K1.9M4.1M4.3M
Net Interest Income211K1.9M4.1M4.3M

Inozyme PharmaInc fundamental ratios Correlations

0.970.950.980.970.85-0.05-0.880.740.420.80.850.781.00.780.741.0-0.730.940.90.83-0.630.870.991.01.0
0.970.960.930.920.880.16-0.930.640.190.680.810.620.960.790.830.98-0.670.940.920.85-0.560.890.960.980.97
0.950.960.950.940.940.12-0.930.750.20.730.90.630.940.710.810.95-0.780.960.880.87-0.680.880.950.950.94
0.980.930.951.00.91-0.16-0.830.850.480.880.930.830.970.670.640.97-0.860.930.840.77-0.790.820.990.960.96
0.970.920.941.00.91-0.18-0.810.860.490.890.930.830.970.630.630.97-0.870.910.820.75-0.790.820.990.960.95
0.850.880.940.910.910.03-0.810.860.20.770.960.640.840.530.620.86-0.90.890.780.73-0.830.810.880.840.83
-0.050.160.12-0.16-0.180.03-0.38-0.42-0.88-0.54-0.19-0.61-0.060.320.55-0.030.290.170.280.410.350.02-0.080.0-0.01
-0.88-0.93-0.93-0.83-0.81-0.81-0.38-0.57-0.03-0.55-0.74-0.48-0.88-0.89-0.88-0.890.6-0.97-0.97-0.980.49-0.8-0.86-0.9-0.89
0.740.640.750.850.860.86-0.42-0.570.60.950.960.860.730.350.240.73-0.960.740.580.5-0.950.640.780.70.69
0.420.190.20.480.490.2-0.88-0.030.60.770.420.870.430.15-0.240.39-0.460.230.160.0-0.490.260.420.370.39
0.80.680.730.880.890.77-0.54-0.550.950.770.890.970.80.450.230.79-0.880.730.610.48-0.860.680.830.770.77
0.850.810.90.930.930.96-0.19-0.740.960.420.890.780.840.480.490.85-0.950.860.720.67-0.90.770.880.830.81
0.780.620.630.830.830.64-0.61-0.480.860.870.970.780.780.490.170.76-0.760.660.580.42-0.740.630.790.740.75
1.00.960.940.970.970.84-0.06-0.880.730.430.80.840.780.790.741.0-0.720.940.90.82-0.620.870.991.01.0
0.780.790.710.670.630.530.32-0.890.350.150.450.480.490.790.730.78-0.330.840.940.87-0.230.690.720.80.81
0.740.830.810.640.630.620.55-0.880.24-0.240.230.490.170.740.730.75-0.330.780.790.87-0.190.680.720.780.77
1.00.980.950.970.970.86-0.03-0.890.730.390.790.850.761.00.780.75-0.730.940.90.82-0.630.890.991.01.0
-0.73-0.67-0.78-0.86-0.87-0.90.290.6-0.96-0.46-0.88-0.95-0.76-0.72-0.33-0.33-0.73-0.76-0.6-0.570.99-0.56-0.8-0.7-0.69
0.940.940.960.930.910.890.17-0.970.740.230.730.860.660.940.840.780.94-0.760.970.94-0.670.820.940.940.94
0.90.920.880.840.820.780.28-0.970.580.160.610.720.580.90.940.790.9-0.60.970.95-0.510.770.880.910.91
0.830.850.870.770.750.730.41-0.980.50.00.480.670.420.820.870.870.82-0.570.940.95-0.470.660.810.840.84
-0.63-0.56-0.68-0.79-0.79-0.830.350.49-0.95-0.49-0.86-0.9-0.74-0.62-0.23-0.19-0.630.99-0.67-0.51-0.47-0.44-0.71-0.6-0.59
0.870.890.880.820.820.810.02-0.80.640.260.680.770.630.870.690.680.89-0.560.820.770.66-0.440.840.870.87
0.990.960.950.990.990.88-0.08-0.860.780.420.830.880.790.990.720.720.99-0.80.940.880.81-0.710.840.990.99
1.00.980.950.960.960.840.0-0.90.70.370.770.830.741.00.80.781.0-0.70.940.910.84-0.60.870.991.0
1.00.970.940.960.950.83-0.01-0.890.690.390.770.810.751.00.810.771.0-0.690.940.910.84-0.590.870.991.0
Click cells to compare fundamentals

Inozyme PharmaInc Account Relationship Matchups

Inozyme PharmaInc fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets47.9M169.4M123.5M139.2M200.8M132.8M
Other Current Liab2.3M6.9M8.5M7.5M12.6M7.2M
Total Current Liabilities3.2M10.0M11.6M14.7M14.7M10.4M
Total Stockholder Equity(33.2M)158.1M109.3M118.6M140.5M87.9M
Net Tangible Assets(33.2M)158.1M109.3M118.4M136.2M74.5M
Property Plant And Equipment Net298K2.6M4.4M3.6M2.6M2.5M
Net Debt(31.6M)(158.6M)(19.9M)(26.1M)12.0M12.6M
Retained Earnings(34.7M)(91.1M)(147.7M)(214.8M)(285.9M)(271.6M)
Accounts Payable901K3.1M2.4M2.5M1.2M2.0M
Cash31.6M159.9M23.3M32.9M34.6M42.4M
Non Current Assets Total484K18.4M8.2M7.8M4.6M7.3M
Non Currrent Assets Other56K3.5M3.4M3.8M1.7M2.3M
Cash And Short Term Investments47.1M159.9M111.8M127.9M188.6M124.4M
Net Receivables104K155K62K115K385K404.3K
Common Stock Shares Outstanding15.2M11.0M23.6M37.8M51.8M28.3M
Short Term Investments15.5M119.7M88.5M95.0M154.0M88.0M
Liabilities And Stockholders Equity47.9M169.4M123.5M139.4M200.8M132.8M
Non Current Liabilities Total77.9M1.3M2.6M6.1M45.7M25.2M
Capital Surpluse1.4M249.2M256.9M333.4M383.4M402.5M
Other Current Assets224K3.3M3.5M3.5M7.3M7.6M
Other Stockholder Equity(76.5M)79.8M133.4M333.6M426.4M447.7M
Total Liab81.2M11.3M14.3M20.8M60.4M32.7M
Net Invested Capital(33.2M)158.1M109.3M122.5M185.2M96.8M
Total Current Assets47.5M151.0M115.3M131.4M196.3M125.5M
Accumulated Other Comprehensive Income5K2K18K(205K)41K43.1K
Net Working Capital44.2M141.0M103.7M116.7M181.6M115.1M
Property Plant Equipment298K2.6M4.4M2.0M2.3M2.1M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Inozyme PharmaInc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Inozyme PharmaInc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inozyme Pharmainc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inozyme Pharmainc Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inozyme PharmaInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
For more information on how to buy Inozyme Stock please use our How to Invest in Inozyme PharmaInc guide.
Note that the Inozyme PharmaInc information on this page should be used as a complementary analysis to other Inozyme PharmaInc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Inozyme Stock analysis

When running Inozyme PharmaInc's price analysis, check to measure Inozyme PharmaInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme PharmaInc is operating at the current time. Most of Inozyme PharmaInc's value examination focuses on studying past and present price action to predict the probability of Inozyme PharmaInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme PharmaInc's price. Additionally, you may evaluate how the addition of Inozyme PharmaInc to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Stocks Directory
Find actively traded stocks across global markets
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Global Correlations
Find global opportunities by holding instruments from different markets
Is Inozyme PharmaInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inozyme PharmaInc. If investors know Inozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inozyme PharmaInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.37)
Return On Assets
(0.28)
Return On Equity
(0.55)
The market value of Inozyme PharmaInc is measured differently than its book value, which is the value of Inozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Inozyme PharmaInc's value that differs from its market value or its book value, called intrinsic value, which is Inozyme PharmaInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inozyme PharmaInc's market value can be influenced by many factors that don't directly affect Inozyme PharmaInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inozyme PharmaInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Inozyme PharmaInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inozyme PharmaInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.